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Abstract
A simple, accurate, precise and fully automated method for the simultaneous determination of
abacavir, lamivudine and zidovudine in pharmaceutical tablets, human serum samples and
drug dissolution studies has been developed. Separation was performed on a 5 lm Zorbax
C18 column (150 · 4.6 mm ID) with methanol:water:phosphate buffer at pH 5.65 (80:10:10;
v/v/v) isocratic elution in less than 7 min with a flow rate of 0.6 mL min)1.Good sensitivity for
all analytes was observed with UV detection at 275 nm. The method allowed quantitation over
the 500–3,000 ng mL)1 range for abacavir and 500–5,000 ng mL)1 range for lamivudine
and zidovudine. The method has been applied, without any interference from excipients or
endogenous substances, for the simultaneous determination of these three compounds in tab-
lets. Human serum and drug dissolution studies.
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Introduction
Trizivir tablets contain three nucleoside
analogues namely abacavir sulfate
(ABA), lamivudine (LAM) and zidovu-
dine (ZDV). These compounds belong to
the category of HIV medicines called
nucleoside reverse transcriptase inhibi-
tors. Trizivir prevents HIV from entering
the nucleus of healthy T-cells, which
subsequently prevents the cells from
producing new viruses and decreases the
amount of virus in the body. ABA, LAM
and ZDV (Fig. 1) are three synthetic
nucleoside analogues.
Trizivir tablets are used for oral
administration. Each ﬁlm-coated tablet
contains 300 mg of abacavir sulfate,
150 mg lamivudine and 300 mg zidovu-
dine [1, 2]. ABA is converted by cellular
enzymes to the active metabolite, carbovir
triphosphate, an analogue of deoxygu-
anosine–5¢ triphosphate. It inhibits the
activity of HIV-1 reverse transcriptase
both by competing with the natural sub-
strate deoxyguanosine-5¢ triphosphate
and its incorporation into viralDNA [1, 2].
ABA is rapidly absorbed following oral
administration with a bioavailability of
about 80%. It is about 50% bound to
plasma proteins. The elimination half-life
is about 1.5 h following a single dose [1, 2].
LAM is the ()) enantiomer of a
dideoxy analogue of cytidine. LAM was
initially developed for the treatment of
HIV infection. Although, generally less
potent than ZDV in inhibiting HIV-1 and
-2 replication in vitro, LAM has very
low cellular cytotoxicity. It is rapidly
absorbed with a bioavailability of
approximately 80% [1, 2].
ZDV is a synthetic nucleoside ana-
logue and structurally similar to thymi-
dine. The principal mode of action of
ZDV triphosphate is the inhibition of
reverse transcriptase via DNA chain
termination after incorporation of the
nucleoside analogue. ZDV is rapidly
absorbed from the gastrointestinal tract
with a bioavailability of about 60–70%.
It passes the blood-brain barrier [1, 2].
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There have been several publications
describing analytical methods for the
determination of ABA, LAM and ZDV
individually. A few methods have been
described for the simultaneous determi-
nation of LAM and ZDV, as binary
mixtures, in biological samples and
pharmaceutical dosage forms [3–6]. Most
of the reported methods require solid-
phase extraction or expensive equipment
unsuitable for routine use in pharmaco-
kinetic and pharmaceutical studies where
many samples need to be analyzed.
However, there have been no reports
concerning the simultaneous determina-
tion of ABA, ZDV and LAM using
HPLC except the recently published
method using chemometric optimization
and LC analysis in tablets [7]. Dissolution
rate studies and related kinetic parameters
of Trizivir tablets and analysis of bio-
logical samples have not been reported.
Drug dissolution testing is an integral
part of pharmaceutical development and
routine quality control monitoring of
drug release characteristics [8]. The pro-
ﬁles, obtained from dissolution rate
studies, have also been used in an attempt
to characterize the in vivo behaviour of
drugs with success [9–11]. They have to
be performed under precisely speciﬁed
conditions (i.e., temperature, volume, and
stirring rate) that mimic processes in the
human gastrointestinal tract.
LC methods are widely used in the
determination of drugs in pharmaceutical
dosage forms and biological samples
[12–14]. The goal of this work was the
development of a new, rapid, sensitive
and fully validated method for the direct
and simultaneous determination of ABA,
LAM and ZDV in raw materials, phar-
maceutical dosage forms and spiked
human serum samples without any time-
consuming extraction or evaporation
steps prior to the assay. This work also
aimed at the simultaneous determination
of ABA, LAM, and ZDV from drug
dissolution tests.
Experimental
Equipment and
Chromatographic Conditions
The chromatographic system consisted of
an HP Agilent 1100 series with an Agilent
series G-13158 DAD detector and an
Agilent 1100 series G-1329 ALS auto-
sampler. The data were handled with
Agilent Technologies HP 1100 software.
Separation was with a 5 lm Zorbax C18
column (150 · 4.6 mm ID) at ambient
temperature. Isocratic elution was with a
mixture of methanol:water:phosphate
buffer at pH 5.65 (80:10:10; v/v/v) at a
ﬂow rate of 0.6 mL min)1. The UV
detector was set at a wavelength of
275 nm. An injection volume of 20 lL
was used. Granisetron was used as an
internal standard.
The dissolution rate studies of ABA,
LAM, ZDV from tablets were performed
on a Caleva 7ST dissolution apparatus
(G.B. Caleva Inc., England).
Chemicals and Reagents
Abacavir, lamivudine and zidovudine
and Trizivir tablets (claimed labelled
amount 300 mg ABA, 150 mg LAM and
300 mg ZDV per tablet) were kindly
supplied by Glaxo-Smith-Kline Pharm.
Inc. (Istanbul, Turkey). The internal
standard, granisetron, was received from
Roche Pharm. Inc (Istanbul, Turkey).
HPLC-grade methanol was purchased
from Merck (Darmstadt, Germany). All
other chemicals (analytical grade) were
obtained from Sigma (St Louis, MO,
USA) or Merck. Double-distilled water
was used throughout.
For dissolution studies, working
solutions of 0.1 M HCl (pH 1.2) and
0.1 M HCl; Na3PO4 mixture (pH 7.4)
was used to mimic the physiological
conditions in gastric and enteric ﬂuids,
respectively.
Stock and Working Solutions
Stock solutions of ABA and LAM
(1.0 mg mL)1) were prepared by dissolv-
ing 10.0 mg of each drug in 10 mL
mobile phase. The standard for ZDV was
made up in methanol to obtain a ﬁnal
concentration of 1.0 mg mL)1. The
internal standard was prepared by dis-
solving 10 mg granisetron in 10 mL of
the mobile phase. Stock solutions were
appropriately diluted with the mobile
phase for the preparation of working
solutions (ﬁnal concentration ranging
between 500 and 5,000 ng mL)1 and the
concentration of IS was maintained at a
constant level of 5,000 ng mL)1. Separate
standard calibration graphs were con-
structed for each component by plotting
the ratio of the peak area of the drug to
that of IS against the drug concentration.
The slopes, intercepts, correlation coefﬁ-
cient, and related validation parameters
such as LOD, LOQ, standard error of
slope and intercept were tabulated for
each compound.
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Fig. 1. Chemical structures of ABA, LAM and ZDV
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All solutions were protected from
light and were used within 24 h to avoid
decomposition. However, chromato-
grams of sample solutions recorded over
a period of a week after preparation did
not show any appreciable change in assay
values.
Ruggedness, Accuracy
and Precision
The ruggedness and intra-day and inter-
day precision and accuracy of the meth-
ods were estimated by assaying ﬁve
replicate samples at three diﬀerent con-
centrations, on the same day and on ﬁve
diﬀerent days over a 2 weeks period. For
checking the ruggedness and precision of
the method, the relative standard devia-
tions (RDSs) were calculated and tabu-
lated. The accuracy of the methods was
expressed as percentage bias [15, 16].
Accuracy of the methods was also deter-
mined by recovery studies.
Procedure for Tablets
Ten tablets, labelled as containing
300 mg ABA, 150 mg LAM and 300 mg
ZDV together with excipients, were
accurately weighed, crushed and ﬁnely
powdered. A weight of the powder
equivalent to one tablet content was
accurately weighed, transferred into a
100 mL calibrated ﬂask, diluted with a
mixture of methanol:mobile phase (9:1;
v/v), stirred for about 10 min and then
completed to volume with the same
solution. This solution was ﬁltered and
the ﬁltrate was collected in a clean ﬂask.
After ﬁltration, solutions were prepared
by taking suitable aliquots of the clear
ﬁltrate, addition of a constant amount of
IS and diluting with mobile phase in
order to obtain the ﬁnal solution.
The amounts of ABA, LAM and ZDV
were calculated from the corresponding
regression equations.
Recovery Studies from Tablets
and Laboratory-Made
Mixtures
To verify the accuracy of the method,
recovery experiments were performed by
adding a known amount of pure drug to
pre-analyzed tablets. The percent recovery
was calculated by comparing the concen-
tration obtained from spiked samples with
the actual added concentration. Thus, the
eﬀect of common tablet formulation ex-
cipients on chromatograms (e.g., tailing,
broadening) was investigated. Recovery
experiments from tablets also showed the
reliability and suitability of the method.
Known amounts of the pure drug and
internal standard, at a constant level, were
added to the ABA, LAM and ZDV tablet
formulation and the mixtures were ana-
lyzed. After ﬁve repeated experiments,
the recoveries were calculated for each
compound.
In order to demonstrate the applica-
bility of the method, the recovery tests
were also carried out by analyzing syn-
thetic mixtures of ABA, LAM and ZDV.
After ﬁve repeated experiments, the
recoveries from these synthetic mixtures
were calculated for each compound.
Analysis of Spiked Serum
Samples
Drug free serum samples, obtained from
healthy individuals, were stored frozen
until assay. After gentle thawing, an ali-
quot of sample was fortiﬁed with ABA,
LAM and ZDV dissolved in selected
media as indicated above. To achieve a
ﬁnal concentration of 1 mg mL)1 and
using 1 mL of acetonitrile as serum de-
naturating and precipitating agent, the
volume was completed to 2.5 mL with
the same serum sample. The tubes were
vortex mixed for 5 min and centrifuged
for 10 min at 5,000g. The supernatant
was carefully taken. The concentration
of ABA, LAM and ZDV was varied
between 500–5,000, 500–5,000 and
500–3,000 ng mL)1, respectively, in hu-
man serum and the concentration of IS
was maintained at a constant level of
5,000 ng mL)1. Separate standard cali-
bration lines were constructed for each
component by plotting the ratio of the
peak area of the drug and the IS against
the drug concentration. The related vali-
dation parameters were tabulated for
each investigated anti-HIV compound.
In Vitro Dissolution Studies
from Tablet Dosage Form
Drug dissolution studies were carried out
in 900 mL of 0.1M HCl (pH 1.2, simu-
lated gastric medium) according to the
USP 24 [17] dissolution procedures for
the single entity products with the use of
a USP paddle-stirrer type of apparatus
for the ﬁrst 60 min at a stirring rate of
75 rpm.
As an alternative method, 700 mL,
0.1 N HCl (pH 1.2; simulated gastric
medium) was used for the ﬁrst 45 min.
After 45 min, the medium pH was ad-
justed to 7.4 by adding Na3PO4 (pH 7.4,
simulated enteric medium). The dissolu-
tion test was continued in this medium
for an additional 75 min using the same
stirring rate. The temperature of the cell
was maintained at 37 ± 0.5 C. At each
sample time, an exact volume of the
sample was withdrawn and immediately
replaced with an identical volume of fresh
medium. At predetermined times, (5, 10,
15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65,
70, 75, 80, 85, 90, 100, 110, 120 min) the
concentration of each drug in the disso-
lution medium was determined using the
related linear regression equation. The
cumulative percentage of drug released in
the media was plotted against time in
order to determine the release proﬁle
from the tablet formulation. The disso-
lution test data were obtained by aver-
aging six parallel studies.
Results and Discussion
The method provides a simple procedure
to determine simultaneously the concen-
tration of ABA, LAM and ZDV in
pharmaceutical dosage forms and spiked
serum samples. To develop a rugged and
suitable LC method, various mobile
phase compositions and diﬀerent types of
columns were tested. Preliminary trials
using mobile phases consisting of a mix-
ture of water, methanol and acetonitrile
in diﬀerent ratios did not give good peak
shapes and analysis times. Addition
of KH2PO4 buffer (7.3 mM) instead of
acetonitrile improved the peak shape of
all compounds as well as the IS. Finally,
by using a buffer pH of 5.65 and a mobile
phase consisting of a mixture of metha-
nol:water:7.3 mM KH2PO4 (8:1:1; v/v/v)
at a ﬂow rate of 0.6 mL min)1, ABA,
LAM, ZDV and the IS, baseline resolu-
tion was obtained and good peak shapes
observed without tailing.
The chemical structure of granisetron
is not similar to the investigated com-
pounds. However, it was chosen as the
IS because it showed a shorter retention
time with better peak shape and better
resolution from the investigated
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compounds peaks, compared with other
potential internal standards. After deter-
mining the optimum conditions, a satis-
factory resolution was obtained in a short
analysis time. For all compounds sharp
and symmetrical well-resolved peaks were
obtained.
The USP suggests that system suit-
ability tests be performed prior to anal-
ysis [17]. The parameters include tailing
factor, capacity factor, theoretical plate
number, retention time, asymmetry fac-
tor, selectivity and RSD% of peak height
or area for repetitive injections. Typi-
cally, at least two of these criteria are
required to demonstrate system suitabil-
ity for the proposed method. Some of the
tests were carried out on freshly prepared
standard solutions including all three
compounds and the IS. Tailing factors of
0.95, 1.15, 1.17, 1.28 were obtained for
LAM, ABA, ZDV and IS, respectively,
with asymmetry factors of 1.05; 0.95; 1.14
and 1.23. The theoretical plate number
(N) and selectivity factor were 1,849 and
3.83 for LAM, 2,064.8 and 2.87 for ABA,
3,340.3 and 1.57 for ZDV. The chro-
matographic conditions described en-
sured adequate retention and resolution
for all analytes. The retention times of
LAM, ABA, ZDV and IS were 2.52; 2.90;
6.52 and 4.71 min. The variation in
retention time for ﬁve replicate injections
of all compounds reference solutions gave
RSDs of 0.903% for LAM, 0.899% for
ABA, 0.172% for ZDV and 0.404% for
the IS. The results obtained from the
system suitability tests satisfy the USP
requirements.
The calibration curves and equations
for ABA, LAM and ZDV in the mobile
phase and serum samples were calculated
by plotting the peak area ratio of
compound to IS vs concentration of
compound in the range of 500–
5,000 ng mL)1 for all compounds in the
mobile phase. Linearity was obtained in
serum samples in the range of 500–
5,000 ng mL)1 for ABA and LAM and
500–3,000 ng mL)1 for ZDV. Linear
regression parameters of the peak area
ratios versus concentration of the com-
pounds are presented in Table 1. These
results showed highly reproducible cali-
bration curves with correlation coefﬁ-
cients of >0.999. The low SE values of
the slope and the intercept in both media
show the precision of the proposed
method. The LOD and LOQ were cal-
culated from the following equations
and using the standard deviation (s) of
response and the slope (m) of the cor-
responding calibration curve.
Table 1. Statistical data for the calibration graphs of ABA, LAM and ZDV in mobile phase and serum samples
Mobile phase Serum
ABA LAM ZDV ABA LAM ZDV
Linearity range (ng mL)1) 500–3,000 500–5,000 500–5,000 500–5,000 500–3,000 500–3,000
Slope 6.483 · 10)4 7.273 · 10)4 2.198 · 10)4 4.580 · 10)4 2.150 · 10)4 2.040 · 10)4
Intercept 5.275 · 10)2 0.125 9.449 · 10)2 7.995 · 10)3 0.421 8.660 · 10)3
Correlation coeﬃcient 0.999 0.999 0.997 0.999 0.999 0.999
SE of slope 1.923 · 10)5 1.089 · 10)5 7.886 · 10)6 6.370 · 10)6 5.660 · 10)6 5.450 · 10)6
SE of intercept 3.108 · 10)2 2.740 · 10)2 1.986 · 10)2 1.610 · 10)2 0.0091 8.810 · 10)3
LOD (ng mL)1) 21.87 63.03 110.32 11.01 95.65 41.18
LOQ (ng mL)1) 72.90 210.09 367.74 33.36 290.47 124.79
Repeatability (RSD%)a 0.513 0.831 0.680 0.317 0.502 1.203
Reproducibility (RSD%)b 2.61 2.25 2.06 1.37 2.49 2.08
aEach value is obtained from ﬁve experiments
bBetween-day reproducibility is determined from ﬁve different runs over a 2 weeks period
Table 2. Determination of ABA, LAM and ZDV in laboratory-made mixtures
Added (ng mL)1) Found (ng mL)1) Recovery (%) RSD (%) Bias (%)
ABA LAM ZDV ABAa LAMa ZDVa ABA LAM ZDV ABA LAM ZDV ABA LAM ZDV
3,000 500 3,000 – 494.99 – – 99.00 – – 1.036 – – 1.002 –
3,000 1,000 3,000 – 999.49 – – 99.95 – – 1.809 – – 0.051 –
3,000 1,500 3,000 – 1,498.67 – – 99.91 – – 1.149 – – 0.089 –
3,000 3,000 3,000 – 2,988.72 – – 99.62 – – 0.481 – – 0.376
Mean recovery (%) 99.51
RSD (%) 0.382
500 1,500 3,000 496.92 – – 99.38 – – 1.56 – – 0.616 – –
1,000 1,500 3,000 999.39 – – 99.94 – – 1.212 – – 0.061 – –
1,500 1,500 3,000 1,505.07 – – 100.34 – – 0.794 – – )0.338 – –
3,000 1,500 3,000 2,955.90 – – 98.53 – – 1.924 – – 1.47 – –
Mean recovery (%) 99.55
RSD (%) 0.788
3,000 1,500 500 – – 494.46 – – 98.89 – – 1.089 – – 1.108
3,000 1,500 1,000 – – 996.39 – – 99.64 – – 1.094 – – 0.361
3,000 1,500 1,500 – – 1,504.01 – – 100.27 – – 0.718 – – )0.267
3,000 1,500 3,000 – – 2,963.60 – – 98.79 – – 1.228 – – 1.213
Mean recovery (%) 99.40
RSD (%) 0.699
aEach value is the mean of three experiments
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LOD = 3.3 s/m; LOQ = 10 s/m [15, 16],
Precision, accuracy and reproducibil-
ity of the method were assessed by per-
forming replicate analysis of standard
solutions in the mobile phase and serum,
Repeatability and reproducibility were
characterized by RSD% (Table 1). Based
on these results, there was no signiﬁcant
difference for the assay, as tested by
within-day (repeatability) and between-
day (reproducibility).
The stability of the reference com-
pounds and sample solutions were
checked by analyzing a standard solution
of the compounds in the mobile phase
stored at +4 C, in the dark against a
sample freshly prepared. The results
demonstrated that the working reference
solutions were stable for up to a week.
Recovery tests were carried out by
analyzing synthetic mixtures of ABA,
LAM and ZDV, with diﬀerent composi-
tion ratios (Table 2).
Each ﬁlm-coated tablet contains the
active ingredients 300 mg of ABA as
abacavir sulfate, 150 mg LAM and
300 mg of ZDV and the inactive ingre-
dients magnesium stearate, microcrys-
talline cellulose, and sodium starch
glyclate. The tablets are coated with a
ﬁlm (Opadry green 03B11434) made of
FD &C Blue No. 2, hypromellose,
polyethylene glycol, titanium dioxide,
and yellow iron oxide. Removal of the
excipients before analysis was found to
be unnecessary.
The substances were eluted as sym-
metrical single peaks, well separated from
the solvent front. The utility of the
method was veriﬁed by means of replicate
estimation of pharmaceutical prepara-
tions and the results were evaluated
statistically (Table 3). The results indicate
that the method is suitable for simulta-
neous determination and routine quality
control of these compounds in pharma-
ceutical formulations.
Recovery studies were also conducted
with the tablets using the standard addi-
tion method to determine the accuracy
and precision. The recovery was mea-
sured by spiking the already analyzed
samples of tablets with known concen-
trations of standard solutions of the
studied compounds. The results (Table 3)
indicate the absence of interferences from
the common pharmaceutical excipients
used in the selected formulations. It is
concluded that the method is sufﬁciently
accurate and precise in order to be ap-
plied to tablet dosage forms.
Validation with spiked human serum
samples was carried out by use of the
appropriate calibration equations ob-
tained with spiked serum samples. Anal-
ysis of drugs from serum samples usually
requires extensive time-consuming sam-
ple preparation and the use of organic
solvents. In this study, the serum proteins
were precipitated by the addition of ace-
tonitrile followed by centrifugation at
5,000g. The supernatant was diluted with
mobile-phase and samples, including
various concentrations of ABA, LAM
and ZDV and a constant amount of IS,
directly injected into the LC column. A
chromatogram obtained from a spiked
serum sample is shown in Fig. 2b with a
blank serum sample in Fig. 2a. The
chromatograms show that there are no
Fig. 2. Representative chromatograms of ABA, LAM, ZDV and IS a drug free serum sample and
b serum samples spiked with 500 ng mL)1 LAM; 1,000 ng mL)1 ABA; 5,000 ng mL)1 IS;
750 ng mL)1 ZDV
Table 3. Results of the assay and the recovery analysis of ABA, LAM and ZDV in tablet dosage forms and human serum
Tablets (mg) Serum samples (ng mL)1)
ABA LAM ZDV ABA LAM ZDV
Labeled claim (mg per tablets) 300.00 150.00 300.00 – – –
Amount found (mg)a 300.34 149.60 300.85 – – –
RSD (%) 0.688 0.659 0.822 – – –
Bias (%) )0.113 0.267 )0.283 – – –
Added (mg) 30.00 15.00 30.00 1,000 500 1,000
Founda 29.84 14.90 30.05 998.90 492.07 1,007.03
Recovery (%) 99.45 99.34 100.17 99.89 98.41 100.70
Bias (%) 0.53 0.67 )0.17 0.11 1.59 )0.703
RSD % of recovery 0.977 0.562 0.880 1.002 1.463 1.108
a Mean value of the ﬁve determination
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interferences from endogenous sub-
stances present in the matrix.
The results and recoveries of known
amounts of ABA, LAM and ZDV added
to serum samples are given in Table 3.
The method provides reproducible re-
sults, is easy to perform, and sensitive
enough for simultaneous determination
of ABA, LAM and ZDV in human ser-
um.
The amounts of ABA, LAM and
ZDV found in tablets by existing analyt-
ical methods are fairly close to the la-
belled amounts [7]. However, the method
described here is more sensitive and pre-
cise having better LOD and LOQ values
and linear range. The determination of
ABA, LAM and ZDV in serum and in
the presence of each other by HPLC was
established for the ﬁrst time.
The method was also applied to the
simultaneous determination of ABA,
LAM and ZDV in dissolution rate stud-
ies. Trizivir tablets, which include
300 mg ABA, 150 mg LAM and 300 mg
ZDV, were investigated by the paddle
dissolution method. The cumulative per-
centage of drug released versus the time
proﬁle is show in Fig. 3 for all com-
pounds. As can be seen in this ﬁgure,
more than 90% ABA and LAM dissolved
in pH 1.2 (gastric media) within 35.0 and
40.0 min, respectively; ZDV did not
dissolve in this medium.
In this ﬁrst test, 900 mL 0.1 N HCl
(pH 1.2) was used for 60 min at
37 ± 0.5 C. In the second test the
medium was changed. For the ﬁrst
45 min, 700 mL 0.1 N HCl (pH 1.2) was
used then 200 mL of 0.2 M trihydrogen
sodium phosphate was added to simulate
enteric ﬂuid (pH 7.4). The concentration
of the drug and the percentage released
were determined at predetermined time
intervals. Figure 3c shows that more than
90% ZDV dissolved in enteric medium
within 85.0 min. The release data were
evaluated according to different models
namely zero order, ﬁrst order, Hixson-
Crowell and Weibull distrubution
(RRSBW) [18, 19] function. All the
kinetics, related rate constants and
parameters are shown in Table 4. For the
release proﬁle (Fig. 3) the best
compliance according to the highest
determination coefﬁcient and lowest
AKAIKE’s information criteria for
ABA, LAM and ZDV dosage form was
found with the Weibull distribution
(RRSBW). The release of ABA, LAM
and ZDV from tablets was determined to
be 63.2%, by the end of 27.10, 28.91, and
86.78 min, respectively. The shape factor
(b) value was found to be lower than 2.5
for ABA and LAM and 4.6 for ZDV. The
release of compounds from the tablets
tested was completed within 40.0 min, for
ABA and LAM and 90.0 min for ZDV.
References
1. Physicians desk reference (PDR) (2003)
56th edn, Medical Economics Company
Inc. Montvale, NJ, p 1664
2. Sweetman SC (2002) Martindale, The
complete drug reference, 33rd edn, Sweet-
man SC (ed) Pharmaceutical Press, Lon-
don, p 612
3. Moore JD, Valette G, Darque A, Zhou XJ,
Sommadassi JP (2000) J Am Soc Mass
Spectrom 11:1134–1143
4. Pereira AS, Kenney KB, Cohen MS, Hall
JE, Eron JJ, Tidwell RR, Dunn JA (2000)
J Chromatogr B 742:173–183
5. Kenney KB, Wring SA, Carr RM, Well
GN, Dunn JA (2000) J Pharm Biomed
Anal 22:967–983
6. Uslu B, Ozkan SA (2002) Anal Chim Acta
466:175–185
7. Djurdjevic P, Laban A, Markovic S,
Stankov MJ (2004) Anal Lett 37:2649–
2667
8. Morrison AB, Campbell JA (1965)
J Pharm Sci 54:1–8
9. Anchisi C, Baroli BM, Fadda AM,
Manconi M, Sinico C, Valenti D (1998)
Farmaco 53:662–666
10. Satiropoulus B, Deutsch T, Plakogiannis
FM (1981) J Pharm Sci 70:422–425
Table 4. Kinetic assessment of release data
Kinetics Parameter ABA LAM ZDV
Zero order kr
0 133.16 71.25 208.45
r2 0.53 0.57 0.83
SWSD 0.22 1.98 2.41
AKAIKE’s information criteria 17.82 15.38 8.51
First order kr 6.03 6.13 5.14
r2 0.70 0.70 0.63
SWSD 5.34 7.86 788.56
AKAIKE’s information criteria 4.40 8.52 49.29
Hixson-Crowell k 3.27 2.46 1.62
R2 0.67 0.67 0.75
SWSD 0.80 0.78 8.38
AKAIKE’s information criteria )25.94 )24.39 24.53
Weibull distribution (RRSBW) T (min) 27.10 28.91 86.78
b 2.21 2.34 4.51
r2 0.90 0.90 0.84
SWSD 529.29 1,910.55 1.04
AKAIKE’s information criteria )53.71 )60.92 )16.26
kr release rate constant of ﬁrst-order kinetics, kr
0 release rate constant of zero-order kinetics, k
release rate constant of Hixson-Crowell kinetics, r2 determination coefﬁcient, SWSD sum of
weighed squared deviations, b shape factor, T (min) time for 63.2% release of the drug
Fig. 3. In vitro dissolution proﬁles of ABA a, LAM b, and ZDV c from tablet dosage form
264 Chromatographia 2007, 65, March (No. 5/6) Original
11. Rowe S, Carless JE (1981) J Pharm Phar-
macol 33:561–565
12. Adamovics JA (ed) (1997) 2nd edn, Chro-
matographic analysis of pharmaceuticals.
Marcel Dekker, New York
13. Snyder LR, Kirkland JJ, Glajch JL (1997)
Practical HPLC method development. 2nd
edn, Wiley, New York
14. Cazes J, Scott RPW (2002) Chromatogra-
phy theory. Marcel Dekker Inc., New York
15. Riley CM, Rosanske TW (1996) Develop-
ment and validation of analytical methods.
Elsevier, New York
16. Swartz ME, Krull IS (1997) Analytical
development and validation. Marcel
Dekker Inc., New York
17. The United States Pharmacopoeia (2000)
24th revision, Easton, Rand Mc Nally
Taunton, MA
18. Higuchi T (1963) J Pharm Sci 52:1145–
1149
19. Langenbucher F (1976) Pharm Ind 38:472–
477
Original Chromatographia 2007, 65, March (No. 5/6) 265
